IMMUNIC AG
6Patents
6Active
6Granted
52Portfolio score
Filing activity: Sep 6, 2018 → Nov 22, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11376232B2 | Vidofludimus for use in the treatment or prevention of viral diseases | Chemistry; Metallurgy | 1 | Active |
| US12037305B2 | Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents | Chemistry; Metallurgy | 0 | Active |
| US11292788B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | Chemistry; Metallurgy | 0 | Active |
| US11877994B2 | Treatment of multiple sclerosis comprising DHODH inhibitors | Human Necessities | 0 | Active |
| US12167994B2 | Vidofludimus for use in the treatment or prevention of viral diseases | Chemistry; Metallurgy | 0 | Active |
| US11877995B2 | Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.